F-1/A: Haoxi Health Technology Announces Unit Offering to Bolster Working Capital

Haoxi Health Technology Limited plans to offer 1,773,049 units, each including a Class A Ordinary Share (or pre-funded warrant), a Series A warrant, and a Series B warrant, to enhance working capital and for general corporate purposes.

Summary

• Haoxi Health Technology Limited is planning a firm commitment offering of 1,773,049 units.
• Each unit comprises one Class A Ordinary Share (or a pre-funded warrant), one Series A warrant, and one Series B warrant.
• The assumed public offering price is $5.64 per unit, based on the last reported sale price on July 12, 2024.
• Pre-funded warrants are exercisable upon issuance at $0.0001 per share and do not expire until fully exercised.
• Series A warrants are exercisable upon issuance at $5.64 per share and have a term of an unspecified number of years.
• Series B warrants are exercisable upon issuance at $0.0001 per share and also have a term of an unspecified number of years.
• The exercise price and number of shares for Series A warrants are subject to adjustment.
• The number of shares for Series B warrants will be determined on the Reset Date, with a pricing floor of $1.128 per share.
• The maximum number of Class A Ordinary Shares underlying the Series A Warrants and Series B Warrants would be an aggregate of approximately 8,865,248 shares and 7,092,199 shares, respectively.
• The company has granted EF Hutton LLC an over-allotment option to purchase up to 15% of the units.
• The offering is subject to CSRC filing procedures.
• The company intends to use the net proceeds for working capital, general corporate purposes, potential acquisitions, and improving internal controls.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The offering itself is a positive move to raise capital, but the numerous risk factors and regulatory uncertainties temper the overall sentiment.

Positives

• The offering aims to strengthen the company's working capital.
• Proceeds may be used for strategic acquisitions and investments.
• The company intends to improve its internal control and compliance systems.

Negatives

• The offering is subject to uncertainties related to PRC regulatory approvals.
• The company is subject to legal and operational risks associated with business operations in China.
• The company is dependent on receipt of funds from its PRC subsidiary, Haoxi Beijing.
• The company faces potential difficulties in transferring cash out of China.
• The company may experience difficulties in complying with PRC regulations.
• The company may be treated as a resident enterprise for PRC tax purposes.
• The company may be subject to PRC tax on dividends and gains on the sale of shares.
• The company may be prohibited from trading on a national exchange under the HFCA Act if the PCAOB is unable to inspect its auditors for two consecutive years.
• The company does not intend to pay dividends for the foreseeable future.
• The company is an emerging growth company and may take advantage of certain exemptions from disclosure requirements.

Risks

• Changes in PRC political and economic policies could adversely affect the company.
• Uncertainties exist regarding the interpretation and enforcement of PRC laws.
• The PRC government exerts substantial influence over the company's business activities.
• The company's offering is subject to CSRC filing procedures.
• The company may experience difficulties in effecting service of legal process or enforcing foreign judgments in China.
• Failure to comply with PRC regulations relating to investments in offshore companies may subject the company to penalties.
• PRC regulations of loans to, and direct investment in, PRC entities by offshore holding companies may limit the company's ability to use offering proceeds.
• The company may be treated as a resident enterprise for PRC tax purposes.
• The company's Class A Ordinary Shares may be prohibited from trading on a national exchange under the HFCA Act.
• The company is an emerging growth company and may take advantage of certain exemptions from disclosure requirements.
• The dual class structure of the company's ordinary shares has the effect of concentrating voting control with the CEO.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for the company's Class A Ordinary Shares.
• Since the company is a controlled company within the meaning of the Nasdaq listing rules, it may follow certain exemptions from certain corporate governance requirements that could adversely affect public shareholders.
• Substantial future sales of the company's Class A Ordinary Shares or the anticipation of future sales of the company's Class A Ordinary Shares in the public market could cause the price of the company's Class A Ordinary Shares to decline.
• The laws of the Cayman Islands may not provide the company's shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United States.

Future Outlook

The company intends to use the proceeds from this offering for working capital and general corporate purposes, acquiring or investing in technologies, solutions or businesses that complement its business, and hiring experienced employees to improve its systems of internal control and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002.

Industry Context

The document highlights the growth of the online marketing industry in China, particularly in the healthcare sector, and the increasing importance of news feed ads and short video marketing solutions.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• It does mention that the operating entity competes with other online marketing solution providers in China on factors such as brand recognition, service quality, and pricing.
• The document also references the iResearch Report, which provides insights into the overall online advertising market in China.

Related Party Transactions

• In April 2024, the Company transferred $350,000 to Haoxi HK, and then Haoxi HK transferred $300,000 to WFOE.
• In May 2024, the Company transferred $950,000 to Haoxi HK.

Stakeholder Impact

• Shareholders face potential dilution from the offering and risks related to PRC regulations.
• Employees may benefit from the company's plans to hire experienced personnel and improve internal controls.
• Customers may benefit from the company's plans to acquire or invest in technologies and solutions that complement its business.
• The company's ability to fund operations and expand its business may be affected by PRC regulations on loans and direct investment.

Next Steps

• Complete the offering of units.
• File with the CSRC within three working days after the completion of the offering.
• Utilize the net proceeds for working capital, acquisitions, and improving internal controls.

Key Dates

Keywords

Haoxi Health Technology, Class A Ordinary Shares, Warrants, Offering, EF Hutton LLC, CSRC, China, Working Capital, Acquisition, Internal Controls